Stock Track | ANI Pharmaceuticals Soars 6.49% Pre-market on Strong Q2 Results and Raised 2025 Guidance

Stock Track

Aug 08

ANI Pharmaceuticals (ANIP) stock surged 6.49% in pre-market trading on Friday following the company's announcement of record second-quarter 2025 financial results and raised full-year guidance. The pharmaceutical company significantly outperformed market expectations, demonstrating strong momentum in its business operations.

For the second quarter of 2025, ANI Pharmaceuticals reported adjusted earnings per share (EPS) of $1.80, substantially beating the analyst estimate of $1.39. The company's sales for the quarter reached $211.371 million, surpassing the expected $187.797 million. This impressive performance underscores the company's ability to execute its strategic initiatives effectively and capitalize on market opportunities.

In light of these strong results, ANI Pharmaceuticals has raised its outlook for the full year 2025. The company now expects annual revenues in the range of $818 million to $843 million, up from previous estimates. Additionally, the adjusted EPS guidance has been increased to a range of $6.98 to $7.35, compared to the earlier FactSet estimate of $6.53. This upward revision in guidance reflects management's confidence in the company's growth trajectory and operational efficiency, further fueling investor optimism and contributing to the stock's pre-market rally.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1191851106"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1191851106\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1191851106?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-08 19:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1191851106","market":"sg","top_or_hot":-1,"title":"Stock Track | ANI Pharmaceuticals Soars 6.49% Pre-market on Strong Q2 Results and Raised 2025 Guidance","media":"Stock Track","content":"<p>ANI Pharmaceuticals (ANIP) stock surged 6.49% in pre-market trading on Friday following the company's announcement of record second-quarter 2025 financial results and raised full-year guidance. The pharmaceutical company significantly outperformed market expectations, demonstrating strong momentum in its business operations.</p>\n\n<p>For the second quarter of 2025, ANI Pharmaceuticals reported adjusted earnings per share (EPS) of $1.80, substantially beating the analyst estimate of $1.39. The company's sales for the quarter reached $211.371 million, surpassing the expected $187.797 million. This impressive performance underscores the company's ability to execute its strategic initiatives effectively and capitalize on market opportunities.</p>\n\n<p>In light of these strong results, ANI Pharmaceuticals has raised its outlook for the full year 2025. The company now expects annual revenues in the range of $818 million to $843 million, up from previous estimates. Additionally, the adjusted EPS guidance has been increased to a range of $6.98 to $7.35, compared to the earlier FactSet estimate of $6.53. This upward revision in guidance reflects management's confidence in the company's growth trajectory and operational efficiency, further fueling investor optimism and contributing to the stock's pre-market rally.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | ANI Pharmaceuticals Soars 6.49% Pre-market on Strong Q2 Results and Raised 2025 Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | ANI Pharmaceuticals Soars 6.49% Pre-market on Strong Q2 Results and Raised 2025 Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-08-08 19:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>ANI Pharmaceuticals (ANIP) stock surged 6.49% in pre-market trading on Friday following the company's announcement of record second-quarter 2025 financial results and raised full-year guidance. The pharmaceutical company significantly outperformed market expectations, demonstrating strong momentum in its business operations.</p>\n\n<p>For the second quarter of 2025, ANI Pharmaceuticals reported adjusted earnings per share (EPS) of $1.80, substantially beating the analyst estimate of $1.39. The company's sales for the quarter reached $211.371 million, surpassing the expected $187.797 million. This impressive performance underscores the company's ability to execute its strategic initiatives effectively and capitalize on market opportunities.</p>\n\n<p>In light of these strong results, ANI Pharmaceuticals has raised its outlook for the full year 2025. The company now expects annual revenues in the range of $818 million to $843 million, up from previous estimates. Additionally, the adjusted EPS guidance has been increased to a range of $6.98 to $7.35, compared to the earlier FactSet estimate of $6.53. This upward revision in guidance reflects management's confidence in the company's growth trajectory and operational efficiency, further fueling investor optimism and contributing to the stock's pre-market rally.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"","article_id":"1191851106","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1191851106","pubTimestamp":1754650943,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"ANI Pharmaceuticals (ANIP) stock surged 6.49% in pre-market trading on Friday following the company's announcement of record second-quarter 2025 financial results and raised full-year guidance. The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"个股赛道|ANI Pharmaceuticals盘前大涨6.49%Q2业绩强劲上调2025年指引","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ANIP":1},"content_text":"ANI Pharmaceuticals (ANIP) stock surged 6.49% in pre-market trading on Friday following the company's announcement of record second-quarter 2025 financial results and raised full-year guidance. The pharmaceutical company significantly outperformed market expectations, demonstrating strong momentum in its business operations.\nFor the second quarter of 2025, ANI Pharmaceuticals reported adjusted earnings per share (EPS) of $1.80, substantially beating the analyst estimate of $1.39. The company's sales for the quarter reached $211.371 million, surpassing the expected $187.797 million. This impressive performance underscores the company's ability to execute its strategic initiatives effectively and capitalize on market opportunities.\nIn light of these strong results, ANI Pharmaceuticals has raised its outlook for the full year 2025. The company now expects annual revenues in the range of $818 million to $843 million, up from previous estimates. Additionally, the adjusted EPS guidance has been increased to a range of $6.98 to $7.35, compared to the earlier FactSet estimate of $6.53. This upward revision in guidance reflects management's confidence in the company's growth trajectory and operational efficiency, further fueling investor optimism and contributing to the stock's pre-market rally.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}